Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline

Phyllis Speiser, Wiebke Arlt, Richard J. Auchus, Laurence S. Baskin, Gerard S. Conway, Deborah P. Merke, Heino F. L. Meyer‐Bahlburg, Walter L. Miller, M. Hassan Murad, Sharon E. Oberfield,

The Journal of Clinical Endocrinology & Metabolism · 2018 · 1.2K citations · 338 references

DOIFull text

Open access

Concepts

Abstract

Newborn screening Cost-effectiveness 1.1 We recommend that all newborn screening programs incorporate screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. (1|s) 1.2 We recommend that first-tier screens use 17hydroxyprogesterone assays standardized to a common technology with norms stratified by gestational age. (1|s) Technical remark: Clinicians should be aware that immunoassays are still in use and remain a source of false-positive results. Specificity may be improved with organic extraction to remove cross-reacting substances. 1.3 We recommend that screening laboratories employ a second-tier screen by liquid chromatographytandem mass spectrometry in preference to all other

References

338